Fintel reports that on December 12, 2025, Jefferies initiated coverage of Moderna (NasdaqGS:MRNA) with a Hold recommendation. Analyst Price Forecast Suggests 29.18% Upside As of December 5, 2025, the ...

The U.S. is in "big danger" of falling behind in vaccine technology research as government funding declines and vaccine ...

NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...

NEW YORK -- When the final Phase 3 data came out last November showing the mRNA vaccines made by Pfizer/BioNTech and Moderna were more than 90% effective, Dr. Anthony Fauci had no words. He texted ...

Moderna announced Thursday that it's launched early-stage clinical trials of an HIV mRNA vaccine. The biotechnology company has teamed up with the nonprofit International AIDS Vaccine Initiative to ...

The initiative forms part of Moderna’s continued investment in US-based infrastructure.

Moderna (NASDAQ: MRNA) extended gains for the seventh consecutive trading session, with the stock closing 2.14% higher at $29 ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $22.0 to $39.0 for Moderna over the last 3 months.

The US Food and Drug Administration intends to put a “black box” warning on Covid-19 vaccines, according to two people familiar with the agency’s plans.

Moderna became a household name during the pandemic because of its leading-edge technology. Investors, as is often the case, extended a positive trend too far into the future. The company's story ...